Myelitis Clinical Trials

1 recruiting

Myelitis Trials at a Glance

82 actively recruiting trials for myelitis are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Wuhan, Boston, and Toronto. Lead sponsors running myelitis studies include Tongji Hospital, PATH, and Monash University.

Treatments under study

About Myelitis Clinical Trials

Looking for clinical trials for Myelitis? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting

Prospective Study of Sinonasal and Skull-base Tumours Management

Nasal NeoplasmNasal Neoplasm BenignSkull Base Neoplasms+3 more
University Medical Centre Ljubljana120 enrolled1 locationNCT05607888
Recruiting
Not Applicable

High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Immune Cell Network

Acute Disseminated EncephalomyelitisEncephalitis Autoimmune
University Hospital, Angers20 enrolled8 locationsNCT06863974
Recruiting

Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)ME/CFS Following COVID-19
Charite University, Berlin, Germany50 enrolled1 locationNCT07529197
Recruiting
Phase 3

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche8 enrolled13 locationsNCT05199688
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 2

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

OsteomyelitisPressure Ulcer, Stage IV
Biocomposites Ltd60 enrolled8 locationsNCT06283979
Recruiting
Phase 4

Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot

Osteomyelitis - FootOsteomyelitis of Lower ExtremitiesOsteomyelitis of the Foot
Michael Garron Hospital1,418 enrolled3 locationsNCT07266753
Recruiting
Phase 4

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Osteomyelitis TibiaTibial FracturesOpen Tibia Fracture
Wake Forest University Health Sciences484 enrolled14 locationsNCT05421741
Recruiting

Reliability and Validation of the WB-MRI Radiological Score in CRMO

PediatricsChronic Recurrent Multifocal Osteomyelitis
IRCCS Azienda Ospedaliero-Universitaria di Bologna15 enrolled1 locationNCT07483853
Recruiting
Phase 4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Neuromyelitis Optica Spectrum Disorder Attack
Chinese PLA General Hospital200 enrolled1 locationNCT07410039
Recruiting
Phase 3

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

Optic NeuritisMyelitisMyelitis, Transverse
Mayo Clinic382 enrolled24 locationsNCT07100990
Recruiting

Chronic Infections and Inflammation in ME/CFS: An Observational Study

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
University of California, San Francisco200 enrolled1 locationNCT07227441
Recruiting
Phase 4

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine

Poliomyelitis
Sinovac Biotech Co., Ltd480 enrolled3 locationsNCT07457060
Recruiting
Phase 2

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Myalgic EncephalomyelitisChronic Fatigue Syndrome
Weill Medical College of Cornell University95 enrolled1 locationNCT04542161
Recruiting
Phase 4

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital198 enrolled1 locationNCT07420296
Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 1Phase 2

Ofatumumab in AQP4-IgG Seropositive NMOSD

Neuromyelitis Optica Spectrum Disorder
Tang-Du Hospital5 enrolled1 locationNCT05504694
Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy RelatedNeuromyelitis Optica Spectrum Disorder
Amgen60 enrolled1 locationNCT05909761
Recruiting
Phase 1

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders
Tongji Hospital69 enrolled1 locationNCT06620809